Danske Bank’s Unicycive Therapeutics UNCY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5 Hold
1
– – ﹤0.01% 1091
2026
Q2
$5 Hold
1
– – ﹤0.01% 1092
2026
Q1
$7 Hold
1
– – ﹤0.01% 1095
2025
Q4
$6 Hold
1
– – ﹤0.01% 1499
2025
Q3
$4 Hold
1
– – ﹤0.01% 1448
2025
Q2
$5 Buy
+1
New +$6 ﹤0.01% 1479

Other funds holding UNCY

Danske Bank's UNCY Position: Q3 2026 in Review

Danske Bank held its Unicycive Therapeutics (UNCY) position steady in Q3 2026 at 1 share worth $5. The position accounts for ﹤0.01% of the portfolio, ranked #1091.

Danske Bank first reported a position in UNCY in Q2 2025 and has held it in 6 quarters since. The position peaked at $7 in Q1 2026. 95 funds tracked by Wall St. Rank hold UNCY as of Q3 2026.

  • Danske Bank held 1 share of Unicycive Therapeutics worth $5 as of Q3 2026.
  • Danske Bank left its Unicycive Therapeutics share count unchanged in Q3 2026.
  • Unicycive Therapeutics made up ﹤0.01% of Danske Bank's portfolio in Q3 2026, its #1091 holding.
  • Danske Bank first reported a position in Unicycive Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Danske Bank's Unicycive Therapeutics position peaked at $7 in Q1 2026.
  • 95 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q3 2026.

Based on Danske Bank's 13F filing for Q3 2026, filed 9 Nov 2026.